Alessandro Sette

Alessandro Sette is an Italian immunologist. He was born on August 11, 1960, in Rome, Italy, to Pietro Sette, a prominent Italian businessman and politician, and Renata Sette. Sette is a professor at La Jolla Institute for Immunology (LJI). He is an adjunct professor at the University of California, San Diego. Sette studies the specific epitopes that the immune system recognizes in cancer, autoimmunity, allergy, and infectious diseases.[1]

Alessandro Sette
BornAugust 11, 1960
Alma materUniversity of Rome
Known forDefining how T cells see antigens

In 1988, Sette moved to San Diego to conduct research at San Diego biotech Cytel. He then co-founded Epimmune. In 2003, Sette joined the faculty of La Jolla Institute for Immunology.[2]

Sette co-leads the Immune Epitope Database (IEDB), an NIAID-funded online database that catalogues epitopes involved in immune system recognition of allergens, infectious diseases, autoantigens, and transplanted tissue in humans and various species.

In 2020, Sette published the first study of SARS-CoV-2 epitopes targeted by the human immune system.[3] He has co-led research into CD8+ and CD4+ T cell responses in COVID-19 patients[4] and studied CD8+ T cell cross-reactivity to SARS-CoV-2 epitopes and other coronaviruses.[5]

Education

Sette received his Laurea in Biological Sciences from the University of Rome, Italy, followed by postdoctoral fellowships in Immunology with Luciano Adorini[6][7] at the C.R.E. Casaccia in Rome, Italy, and Howard Grey[8][9] at the National Jewish Center for Immunology and Respiratory Medicine in Denver, Colorado.

Publications/Patents

Dr. Sette is a coauthor of over 900 peer-reviewed publications, and is an inventor on 41 US issued patents. He has a H-factor of 170, and is identified by Clarivate as a Highly Cited Researcher.

Research

In the mid-80s, at the same time as  Paul Allen in Emil Unanue’s lab, Sette together with Soren Buus in Howard Grey’s lab reported the first direct evidence that MHC molecules’ function is to bind antigenic peptides[10][11] and present them to the T cell receptor, which triggers a T cell response. Follow-up work explained MHC restriction.[12][13]

References
  1. "» Sette Lab". www.lji.org. Retrieved January 5, 2021.
  2. Sette, Alessandro (March 28, 2017). "Portrait of an optimist". Human Vaccines & Immunotherapeutics. 13 (6): 1210–1212. doi:10.1080/21645515.2017.1312175. ISSN 2164-5515. PMC 5489282. PMID 28350507.
  3. Grifoni, Alba; Weiskopf, Daniela; Ramirez, Sydney I.; Mateus, Jose; Dan, Jennifer M.; Moderbacher, Carolyn Rydyznski; Rawlings, Stephen A.; Sutherland, Aaron; Premkumar, Lakshmanane; Jadi, Ramesh S.; Marrama, Daniel (June 25, 2020). "Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals". Cell. 181 (7): 1489–1501.e15. doi:10.1016/j.cell.2020.05.015. ISSN 0092-8674. PMC 7237901. PMID 32473127.
  4. Moderbacher, Carolyn Rydyznski; Ramirez, Sydney I.; Dan, Jennifer M.; Grifoni, Alba; Hastie, Kathryn M.; Weiskopf, Daniela; Belanger, Simon; Abbott, Robert K.; Kim, Christina; Choi, Jinyong; Kato, Yu (November 12, 2020). "Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity". Cell. 183 (4): 996–1012.e19. doi:10.1016/j.cell.2020.09.038. ISSN 0092-8674. PMC 7494270. PMID 33010815.
  5. Mateus, Jose; Grifoni, Alba; Tarke, Alison; Sidney, John; Ramirez, Sydney I.; Dan, Jennifer M.; Burger, Zoe C.; Rawlings, Stephen A.; Smith, Davey M.; Phillips, Elizabeth; Mallal, Simon (October 2, 2020). "Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans". Science. 370 (6512): 89–94. Bibcode:2020Sci...370...89M. doi:10.1126/science.abd3871. ISSN 0036-8075. PMC 7574914. PMID 32753554.
  6. Sette, Alessandro; Colizzi, Vittorio; Appella, Ettore; Doria, Gino; Adorini, Luciano (1986). "Analysis of lysozyme-specific immune responses by synthetic peptides. I. Characterization of antibody and T cell-mediated responses to the N-terminal peptide of hen egg-white lysozyme". European Journal of Immunology. 16 (1): 1–6. doi:10.1002/eji.1830160102.
  7. Sette, Alessandro; Doria, Gino; Adorini, Luciano (August 1986). "A microcomputer program for hydrophilicity and amphipathicity analysis of protein antigens". Molecular Immunology. 23 (8): 807–810. doi:10.1016/0161-5890(86)90065-9.
  8. Buus, S.; Sette, A.; Colon, S. M.; Jenis, D. M.; Grey, H. M. (December 26, 1986). "Isolation and characterization of antigen-Ia complexes involved in T cell recognition". Cell. 47 (6): 1071–1077. doi:10.1016/0092-8674(86)90822-6. ISSN 0092-8674. PMID 3490919.
  9. Sette, A.; Buus, S.; Colon, S.; Smith, J. A.; Miles, C.; Grey, H. M. (July–August 1987). "Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells". Nature. 328 (6129): 395–399. doi:10.1038/328395a0. ISSN 0028-0836. PMID 3497349.
  10. Buus, S.; Sette, A.; Colon, S. M.; Jenis, D. M.; Grey, H. M. (December 26, 1986). "Isolation and characterization of antigen-Ia complexes involved in T cell recognition". Cell. 47 (6): 1071–1077. doi:10.1016/0092-8674(86)90822-6. ISSN 0092-8674. PMID 3490919.
  11. Sette, A.; Buus, S.; Colon, S.; Smith, J. A.; Miles, C.; Grey, H. M. (July–August 1987). "Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells". Nature. 328 (6129): 395–399. doi:10.1038/328395a0. ISSN 0028-0836. PMID 3497349.
  12. Demotz, S.; Grey, H. M.; Sette, A. (August 31, 1990). "The minimal number of class II MHC-antigen complexes needed for T cell activation". Science. 249 (4972): 1028–1030. doi:10.1126/science.2118680. ISSN 0036-8075. PMID 2118680.
  13. Sette, A.; Vitiello, A.; Reherman, B.; Fowler, P.; Nayersina, R.; Kast, W. M.; Melief, C. J.; Oseroff, C.; Yuan, L.; Ruppert, J.; Sidney, J. (December 15, 1994). "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes". Journal of Immunology. 153 (12): 5586–5592. ISSN 0022-1767. PMID 7527444.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.